Fayowole D. Ogunbiyi

Fayowole D. Ogunbiyi

Auto-generated profile, based on publicly available information

Fayowole D. Ogunbiyi

Department of Biochemistry, Adekunle Ajasin University, Akungba-Akoko, Nigeria

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 June 2026 in Journal of Computer-Aided Molecular Design
Verified
Journal Article
Closed access
PAPrecious Ayorinde Akinnusi
Precious Ayorinde Akinnusi
GEGladys D. Egunjobi
Gladys D. Egunjobi
AAAyomide Akinnusi
Ayomide Akinnusi
TOTomilola Oluwadare
Tomilola Oluwadare
FOFayowole Ogunbiyi
Fayowole Ogunbiyi
SSSidiqat Adamson Shodehinde
Sidiqat Adamson Shodehinde

13 September 2026 in Scientific Reports
Verified
Journal Article
Open access
PDF file
PAPrecious Ayorinde Akinnusi
Precious Ayorinde Akinnusi
GEGladys D. Egunjobi
Gladys D. Egunjobi
AAAyomide J. Akinnusi
Ayomide J. Akinnusi
FOFayowole D. Ogunbiyi
Fayowole D. Ogunbiyi
Cyclin-dependent kinase 2 (CDK2) is a therapeutic target of interest, but selective inhibition remains challenging because ATP-competitive inhibitors often engage related CDK family members. Here, we developed a selectivity-aware computational workflow to prioritize CDK2-biased kinase inhibitor candidates using curated ChEMBL bioactivity data, target-specific machine-learning models, scaffold-guided analog generation, applicability-domain filtering, medicinal-chemistry triage, control-compound benchmarking, molecular docking, and MM-GBSA rescoring. IC 50 data for CDK1, CDK2, CDK4, CDK6, CDK7, and CDK9 yielded 7,067 compound-target records and 4,879 standardized compounds. Extra Trees models trained with RDKit descriptors and Morgan fingerprints provided useful multi-target activity prediction, with the CDK2 model achieving MAE = 0.523, RMSE = 0.699, and R 2 = 0.607 in random-split evaluation. Predicted CDK2 selectivity margin recovered measured CDK2-biased compounds more effectively than predicted CDK2 potency alone, including ROC-AUC = 0.921 and average precision = 0.846 in retrospective enrichment and ROC-AUC = 0.888 ± 0.061 in scaffold-held-out enrichment. Focused sulfonamide analog generation and filtering prioritized 221 CDK2-biased candidates, of which six showed CDK2-favored docking in both SP and XP modes. MM-GBSA rescoring further identified one compound with convergent CDK2 preference across SP docking, XP docking, and post-docking energetic rescoring. This workflow provides a reproducible strategy for enriching CDK2-biased analogs for experimental evaluation.